Interestingly, while BCL-2 was also highly expressed pre-CDA the level of this protein returned to healthy control ranges post-CDA (Fig. 2d) (pre vs. healthy adj p = 3.05 × 10–5, pre vs. post adj p = 3.18 × 10–12), likely reflecting the change in tumour burden in these patients. The gene discussed is BCL2; the disease is neoplasm.